EVLO
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2023 Q3 | -71.12 | $0 | -$10M |
| 2023 Q2 | -3.78 | $0 | -$20M |
| 2023 Q1 | -4.57 | $0 | -$20M |
| 2022 Q4 | -4.29 | $0 | -$23M |
| 2022 Q3 | -5.66 | $0 | -$23M |
| 2022 Q2 | -8.07 | $0 | -$27M |
| 2022 Q1 | -11.14 | $0 | -$29M |
| 2021 Q4 | -10.71 | $0 | -$27M |